Characterization of the murine leukemia virus protease and its comparison with the human immunodeficiency virus type 1 protease

Journal of General Virology

Volumn 87, Issue 5, 2006, Pages 1321-1330

  Fehér, Anita ^a   Boross, Péter ^a   Sperka, Tamás ^a   Miklóssy, Gabriella ^a   Kádas, János ^a   Bagossi, Péter ^a   Oroszlan, Stephen ^b   Weber, Irene T ^c   Tözsér, József ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b NATIONAL CANCER INSTITUTE   (United States)

^c GEORGIA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4,7 DIBENZYL 2,3,4,5,6,7 HEXAHYDRO 5,6 DIHYDROXY 1,3 BIS[4 (HYDROXYMETHYL)BENZYL] 2H 1,3 DIAZEPIN 2 ONE; AMPRENAVIR; GAG PROTEIN; INDINAVIR; KH 164; NELFINAVIR; OLIGOPEPTIDE; PROTEINASE; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG DESIGN; DRUG POTENCY; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME SPECIFICITY; ESCHERICHIA COLI; FLUOROMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; INTERMETHOD COMPARISON; LIFE CYCLE; MOLECULAR PHYLOGENY; MURINE LEUKEMIA VIRUS; NONHUMAN; PH; PHOTOMETRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN PURIFICATION; SPECIES DIFFERENCE; VIRION;

AMINO ACID SEQUENCE; ANIMALS; CARBAMATES; ESCHERICHIA COLI; GENE PRODUCTS, GAG; HIV PROTEASE; HIV PROTEASE INHIBITORS; HUMANS; HYDROGEN-ION CONCENTRATION; LEUKEMIA VIRUS, MURINE; MICE; MOLECULAR SEQUENCE DATA; NIH 3T3 CELLS; OLIGOPEPTIDES; PEPTIDE HYDROLASES; RECOMBINANT PROTEINS; SPECIES SPECIFICITY; SULFONAMIDES;

ESCHERICHIA COLI; HUMAN IMMUNODEFICIENCY VIRUS 1; MURINE LEUKEMIA VIRUS;

EID: 33646156631     PISSN: 00221317     EISSN: None     Source Type: Journal    
DOI: 10.1099/vir.0.81382-0     Document Type: Article

References (46)

1. Bagossi, P., Kádas, J., Miklóssy, G., Boross, P., Weber, I. T. & Tözsér, J. (2004). Development of a microtiter plate fluorescent assay for inhibition studies on the HTLV-1 and HIV-1 proteinases. J Virol Methods 119, 87-93.
2. Barbaro, G., Scozzafava, A., Mastrolorenzo, A. & Supuran, C. T. (2005). Highly active antiretroviral therapy: current state of the art, new agents and their pharmacological interactions useful for improving therapeutic outcome. Curr Pharm Des 11, 1805-1843.
3. Black, P. L., Downs, M. B., Lewis, M. G., Ussery, M. A., Dreyer, G. B., Petteway, S. R., Jr & Lambert, D. M. (1993). Antiretroviral activities of protease inhibitors against murine leukemia virus and simian immunodeficiency virus in tissue culture. Antimicrob Agents Chemother 37, 71-77.
4. Black, P. L., Ussery, M. A., Barney, S. & 7 other authors (1996). Effects of SKF 108922, an HIV-1 protease inhibitor, on retrovirus replication in mice. Antiviral Res 29, 175-186.
5. Boross, P., Bagossi, P., Copeland, T. D., Oroszlan, S., Louis, J. M. & Tözsér, J. (1999). Effect of substrate residues on the P2′ preference of retroviral proteinases. Eur J Biochem 264, 921-929.
6. Brunelle, M.-N., Brakier-Gingras, L. & Lemay, G. (2003). Replacement of murine leukemia virus readthrough mechanism by human immunodeficiency virus frameshift allows synthesis of viral proteins and virus replication. J Virol 77, 3345-3350.
7. gag. AIDS Res Hum Retroviruses 5, 259-268.
8. Campbell, S., Oshima, M., Mirro, J., Nagashima, K. & Rein, A. (2002). Reversal by dithiothreitol treatment of the block in murine leukemia virus maturation induced by disulfide cross-linking. J Virol 76, 10050-10055.
9. Cannon, K., Qin, L., Schumann, G. & Boeke, J. D. (1998). Moloney murine leukemia virus protease expressed in bacteria is enzymatically active. Arch Virol 143, 381-388.
10. Crawford, S. & Goff, S. P. (1985). A deletion mutation in the 5′ part of the pol gene of Moloney murine leukemia virus blocks proteolytic processing of the gag and pol polyproteins. J Virol 53, 899-907.
11. Erickson-Viitanen, S., Manfredi, J., Viitanen, P., Tribe, D. E., Tritch, R., Hutchison, C. A., III, Loeb, D. D. & Swanstrom, R. (1989). Cleavage of HIV-1 gag polyprotein synthesized in vitro: sequential cleavage by the viral protease. AIDS Res Hum Retroviruses 5, 577-591.
12. Fehér, A., Weber, I. T., Bagossi, P. & 7 other authors (2002). Effect of sequence polymorphism and drug resistance on two HIV-1 Gag processing sites. Eur J Biochem 269, 4114-4120.
13. Fehér, A., Boross, P., Sperka, T., Oroszlan, S. & Tözsér, J. (2004). Expression of the murine leukemia virus protease in fusion with maltose-binding protein in Escherichia coli. Protein Expr Purif 35, 62-68.
14. Gorelick, R. J., Henderson, L. E., Hanser, J. P. & Rein, A. (1988). Point mutants of Moloney murine leukemia virus that fail to package viral RNA: evidence for specific RNA recognition by a "zinc finger-like" protein sequence. Proc Natl Acad Sci U S A 85, 8420-8424.
15. Hyland, L. J., Tomaszek, T. A., Jr & Meek, T. D. (1991). Human immunodeficiency virus-1 protease. 2. Use of pH rate studies and solvent kinetic isotope effects to elucidate details of chemical mechanism. Biochemistry 30, 8454-8463.
16. Ido, E., Han, H.-P., Kezdy, F. J. & Tang, J. (1991). Kinetic studies of human immunodeficiency virus type 1 protease and its active-site hydrogen bond mutant A28S. J Biol Chem 266, 24359-24366.
17. Imamichi, T. (2004). Action of anti-HIV drugs and resistance: reverse transcriptase inhibitors and protease inhibitors. Curr Pharm Des 10, 4039-4053.
18. Katoh, I., Yoshinaka, Y., Rein, A., Shibuya, M., Odaka, T. & Oroszlan, S. (1985). Murine leukemia virus maturation: protease region required for conversion from "immature" to "mature" core form and for virus infectivity. Virology 145, 280-292.
19. Kiernan, R. E. & Freed, E. O. (1998). Cleavage of the murine leukemia virus transmembrane Env protein by human immunodeficiency virus type 1 protease: transdominant inhibition by matrix mutations. J Virol 72, 9621-9627.
20. Kohl, N. E., Diehl, R. E., Rands, E., Davis, L. J., Hanobik, M. G., Wolanski, B. & Dixon, R. A. F. (1991). Expression of active human immunodeficiency virus type 1 protease by noninfectious chimeric virus particles. J Virol 65, 3007-3014.
21. Kotler, M., Danho, W., Katz, R. A., Leis, J. & Skalka, A. M. (1989). Avian retroviral protease and cellular aspartic proteases are distinguished by activities on peptide substrates. J Biol Chem 264, 3428-3435.
22. Lai, M. H., Tang, J., Wroblewski, V. & 7 other authors (1993). Impeded progression of Friend disease in mice by an inhibitor of retroviral proteases. J Acquir Immune Defic Syndr 6, 24-31.
23. Luban, J. & Goff, S. P. (1991). Binding of human immunodeficiency virus type 1 (HIV-1) RNA to recombinant HIV-1 gag polyprotein. J Virol 65, 3203-3212.
24. Menéndez-Arias, L., Young, M. & Oroszlan, S. (1992). Purification and characterization of the mouse mammary tumor virus protease expressed in Escherichia coli. J Biol Chem 267, 24134-24139.
25. Menéndez-Arias, L., Gotte, D. & Oroszlan, S. (1993). Moloney murine leukemia virus protease: bacterial expression and characterization of the purified enzyme. Virology 196, 557-563.
26. 3′ of Moloney murine leukemia virus protease. J Biol Chem 269, 16795-16801.
27. Menéndez-Arias, L., Tözsér, J. & Oroszlan, S. (2004). Moloney murine leukemia virus retropepsin. In Handbook of Proteolytic Enzymes, 2nd edn, pp. 176-178. Edited by A. J. Barrett, N. D. Rawlings & J. F. Woessner. London: Elsevier.
28. Naso, R. B., Karshin, W. L., Wu, Y. H. & Arlinghaus, R. B. (1979). Characterization of 40,000- and 25,000-dalton intermediate precursors to Rauscher murine leukemia virus gag gene products. J Virol 32, 187-198.
29. Oroszlan, S. & Luftig, R. B. (1990). Retroviral proteinases. Curr Top Microbiol Immunol 157, 153-185.
30. Oshima, M., Muriaux, D., Mirro, J., Nagashima, K., Dryden, K., Yeager, M. & Rein, A. (2004). Effects of blocking individual maturation cleavages in murine leukemia virus Gag. J Virol 78, 1411-1420.
31. Pettit, S. C., Simsic, J., Loeb, D. D., Everitt, L., Hutchinson, C. A., III & Swandtrom, R. (1991). Analysis of retroviral protease cleavage sites reveals two types of cleavage sites and the structural requirements of the P1 amino acid. J Biol Chem 266, 14539-14547.
32. Polgár, L., Szeltner, Z. & Boros, I. (1994). Substrate-dependent mechanisms in the catalysis of human immunodeficiency virus protease. Biochemistry 33, 9351-9357.
33. Powell, S. K., Artlip, M., Kaloss, M., Brazinski, S., Lyons, R., McGarrity, G. J. & Otto, E. (1999). Efficacy of antiretroviral agents against murine replication-competent retrovirus infection in human cells. J Virol 73, 8813-8816.
34. Sambrook, J., Fritsch, E. F. & Maniatis, T. (1989). Molecular Cloning: a Laboratory Manual, 2nd edn. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory.
35. Schechter, I. & Berger, A. (1967). On the size of the active site in proteases. I. Papain. Biochem Biophys Res Commun 27, 157-162.
36. Shehu-Xhilaga, M., Crowe, S. M. & Mak, J. (2001). Maintenance of the Gag/ Gag-Pol ratio is important for human immunodeficiency virus type 1 RNA dimerization and viral infectivity. J Virol 75, 1834-1841.
37. Thomas, C. E., Ehrhardt, A. & Kay, M. A. (2003). Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet 4, 346-358.
38. Tözsér, J., Bláha, I., Copeland, T. D., Wondrak, E. M. & Oroszlan, S. (1991). Comparison of the HIV-1 and HIV-2 proteinases using oligopeptide substrates representing cleavage sites in Gag and Gag-Pol polyproteins. FEBS Lett 281, 77-80.
39. 3′ subsites of HIV proteinases. Biochemistry 31, 4793-4800.
40. Tözsacer, J., Friedman, D., Weber, I. T., Blaha, I. & Oroszlan, S. (1993). Studies on the substrate specificity of the proteinase of equine infectious anemia virus using oligopeptide substrates. Biochemistry 32, 3347-3353.
41. Tözsér, J., Bagossi, P., Weber, I. T., Copeland, T. D. & Oroszlan, S. (1996). Comparative studies on the substrate specificity of avian myeloblastosis virus proteinase and lentiviral proteinases. J Biol Chem 271, 6781-6788.
42. Weber, I. T., Wu, J., Adomat, J., Harrison, R. W., Kimmel, A. R., Wondrak, E. M. & Louis, J. M. (1997). Crystallographic analysis of human immunodeficiency virus 1 protease with an analog of the conserved CA-p2 substrate - interactions with frequently occurring glutamic acid residue at P2′ position of substrates. Eur J Biochem 249, 523-530.
43. Williams, J. W. & Morrison, J. F. (1979). The kinetics of reversible tight-binding inhibition. Methods Enzymol 63, 437-467.
44. Wondrak, E. M., Louis, J. M. & Oroszlan, S. (1991). The effect of salt on the Michaelis Menten constant of the HIV-1 protease correlates with the Hofmeister series. FEBS Lett 280, 344-346.
45. Yoshinaka, Y. & Luftig, R. B. (1982). p65 of Gazdar murine sarcoma viruses contains antigenic determinants from all four of the murine leukemia virus (MuLV) gag polypeptides (p15, p12, p30, and p10) and can be cleaved in vitro by the MuLV proteolytic activity. Virology 118, 380-388.
46. Yoshinaka, Y., Katoh, I., Copeland, T. D. & Oroszlan, S. (1985). Murine leukemia virus protease is encoded by the gag-pol gene and is synthesized through suppression of an amber termination codon. Proc Natl Acad Sci U S A 82, 1618-1622.